• Juri Chung, Shari B Brosnahan, Shahidul Islam, Diana Altshuler, Peter Spiegler, Wai Kin Li, Wai Man Wang, and Xian Jie Cindy Chen.
• Department of Pharmacy, NYU Langone Hospital- Long Island, Mineola, NY, USA. Electronic address: Juri.chung@nyulangone.org.
• J Crit Care. 2023 Aug 1; 76: 154291154291.

PurposeTocilizumab has been shown to decrease mortality when used concomitantly with steroids in COVID-19 with 8 mg/kg (max 800 mg) being the standard dose. Our study sought to assess whether a low dose (400 mg) shows similar benefit compared to a high dose for COVID patients concurrently on the same median dose of steroids.Materials/MethodsA retrospective, multihospital observational study of COVID-19 patients who received tocilizumab in conjunction with steroids between March 2020 and August 2021 was conducted.ResultsA total of 407 patients were analyzed with low dose group being significantly more ill at baseline as a higher percentage of patients received vasopressors, were admitted to the ICU and on mechanical ventilation. In the propensity-matched analysis, both groups receiving a median dexamethasone equivalent dose of 10 mg showed no difference in 28-day mortality (p = 0.613). The high dose group had a higher rate of fungal and viral infections.ConclusionCompared to low dose tocilizumab, the high dose did not provide additional efficacy and mortality benefit but resulted in higher fungal and viral infections. This study illustrates that low dose tocilizumab can be an alternative to high dose during a drug shortage of tocilizumab without compensating for efficacy and safety, conserving resources for more patients.Copyright © 2023 Elsevier Inc. All rights reserved.

14 keywords...

hide…